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approaches to repeat screening at critical junctures such as treatment 
completion and relapse.
Patients agreed to further referrals to: % of patients
Lung support nurse 75
Further input from doctor 70
Occupational therapy 49
Social work 39
Sources of additional written information 37
Physiotherapy 29
Dietician 27
Psychology/Psychiatry 13
Pastoral Care 8
B6-06 Health Services, Supportive Care & QOL, Tue, 13:45 - 15:30
Assessing the quality of a lung cancer service
O’Rourke, Noelle 
West of Scotland Lung Cancer Network, Glasgow, UK
Background: In 2002 national cancer registry based audit data demon-
strated that for lung cancer in Scotland there were statistically signiﬁ-
cant survival differences depending upon where the patient lived. This 
correlated with data on patterns of care, conﬁrming differences in use 
of active cancer treatment by geographical area. The West of Scotland 
Lung Cancer Network was established in 2002 with the aim of deliver-
ing consistent high quality care across all hospital units with equity of 
access to lung cancer specialists. Prospective lung cancer audit was 
established for the regional network in 2003 with a dataset including 
demographic data, treatment details and outcome. This current study 
aims to assess changes in patterns of care since 2002 and compares 
the six geographical areas within the region on quality of lung cancer 
service.
Method: On 2005 audit data eight indicators of quality of care were 
used to compare the current service across geographical areas:
1. Comprehensive lung cancer care to local population as measured by 
case ascertainment in audit compared to national cancer registry data
2. Multidisciplinary (MDT) team discussion of patient management
3. Histological diagnostic rate
4. Surgical resection rate
5. Chemotherapy use in small cell lung cancer (SCLC) patients
6. Patients receiving no active anti-cancer therapy
7. Recruitment to clinical trials
8. One year survival 
The national audit data published in 2002 provided a baseline compari-
son.
Results: Case ascertainment for the region was 82.8%, but ranged from 
63.4-96.1% across the six areas. MDT input was achieved in mean 
84.2% patients but ranged from 60.4-96.5%. Histological diagnosis 
mean rate was 81.9%, range 76.9-86.4%. Surgical resection varied 
from 6.5-22% (mean 10.7%). Chemotherapy was used in 62.4% SCLC 
patients but ranged from 35.7-73.3%. In the 2002 data 43% patients re-
ceived no active treatment which had fallen to a mean of 25% in 2005 
but areas varied 19.4-35.1%. Recruitment to trials was poor average 
1.6%, range 0-4.2%. One year survival for 2002 ranged from 21.6-
25.8%, but for 2004 patients across the region ranged from 26.7-33%.
Conclusions: With the development of a lung cancer network the treat-
ment rates and survival for lung cancer can be shown to be improved. 
Geographical differences in care still persist however and this assess-
ment will be used to stimulate further improvements.
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Symptom assessment in small cell lung cancer (sclc) in a 
randomized trial: a psychometric analysis of Patient Symptom 
Assessment in Lung Cancer (PSALC)
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Mary E.3 
1 Analysis Group, Inc., Boston, MA, USA 2 GlaxoSmithKline, Colleg-
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Background: Lung cancer symptoms can be very burdensome for 
patients with SCLC and can result in impairment in quality of life and 
health status. PSALC is a symptom scale developed for use in patients 
with SCLC for assessment of 9 symptoms (shortness of breath, cough, 
chest pain, hemoptysis, appetite loss, sleep interference, hoarseness, 
fatigue, interference with daily activities) scored from 1 (not at all) to 
4 (very much), but it has not been formally validated. The objective of 
this study is to evaluate the validity of the PSALC through a psycho-
metric analysis of trial data.
Methods: Data were analyzed from a randomized, open-label, 
multicenter trial with 71 patients with SCLC receiving oral topotecan 
with best supportive care (BSC) and 70 patients receiving BSC alone. 
PSALC and EQ-5D were administered to patients at baseline and at 
3-week intervals at subsequent visits. Internal consistency, construct 
validity, reliability, and responsiveness to change in clinical status were 
evaluated.
Results: Factor analysis using baseline PSALC evaluations (n=132) 
indicated that all 9 symptom questions can be summarized as one fac-
tor, therefore, PSALC total score was used for psychometric analysis. 
Weighted Cronbach’s alpha from all visits was 0.78. Construct validity 
was supported by the association of higher PSALC total score (worse 
symptoms) with worse ECOG performance status (Table). The PSALC 
total score was also signiﬁcantly correlated with EQ-5D utility index 
and EQ-5D VAS score at baseline and at follow-up visits (Pearson 
correlation coefﬁcient [CC]=-0.598 with EQ-5D utility index; Pear-
son CC=-0.594 with EQ-5D VAS score; using evaluations at all time 
points; both p<0.0001). Reliability was supported by intraclass CC of 
0.68 for PSALC total scores evaluated before any change in clinical 
status, and concordance CC of 0.69, calculated using PSALC total 
scores at baseline and before ﬁrst visit. The PSALC total score was 
responsive to change in clinical status from baseline to tumor re-
sponse (responsiveness statistic [RS] =-0.99) and to tumor progression 
(RS=0.94).
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ECOG Baseline Visit 1 Visit 2 Visit 3 Visit 4
0 12.3 14.7 13.6 13.8 12.7
1 16.4 15.5 14.6 14.1 15.2
2 17.6 17.8 16.3 16.1 16.9
3 n/a 22.4 22.8 19.6 20.7
p-value 0.0002 0.0017 <0.0001 0.0048 0.0011
N 132 98 77 66 49
 
Conclusions: Retrospective analysis of trial data suggests that PSALC 
is a reliable, valid, and responsive scale for measuring SCLC symp-
toms. If feasible in SCLC population, a prospective validation study 
could be used to further evaluate the validity of this symptom scale.
Session B7: BSTB: Molecular Diagnostics & Pathology 
Tuesday, September 4
B7-01 BSTB: Molecular Diagnostics & Pathology, Tue, 13:45 - 15:30
Aberrant pattern of histone H4 modification in human lung 
carcinoma
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Background: Post-translational modiﬁcations in the tails of nucleoso-
mal core histones are emerging as important signalling processes con-
trolling a wide variety of functions. Indeed they play a crucial role in 
chromatin packaging, gene expression and genome stability. Therefore, 
perturbation of this epigenetic information is likely to be involved in 
the development of cancer. Although some studies identiﬁed an altered 
activity of histone-modifying enzymes in tumors, little is known about 
the post-translational modiﬁcations of histones in these malignancies. 
Methods: By using immunohistochemistry, we studied the pattern of 
histone H4 modiﬁcations in a series of 100 primary non small cell lung 
tumors comprising 51 squamous carcinoma and 49 adenocarcinoma. 
Speciﬁc antibodies recognizing acetylated histone H4 at positions K5, 
K8 and K16 and trimethylated histone H4 at position K20 were used 
on frozen tissue sections with an automated immunostainer Ventana in 
order to standardize the staining. Normal lung epithelial cells (al-
veolar and bronchial basal cells) were taken as internal controls and 
their score used for determination of the cut off score to discriminate 
between positive (score at least equal to normal) and negative (score 
lower than normal) cases. 
Results: Our data show that, as compared to normal lung, lysines 5 
and 8 of histone H4 are hyperacetylated in 48% and 40% of all tumors 
respectively, more frequently in squamous carcinoma than in adenocar-
cinoma (p=0.009 and p=0.0002 respectively). In contrast, acetylation 
at Lys16 and trimethylation at Lys20 are lost in 52% and 47% of the 
tumors respectively. Across histological types loss of trimethylation at 
Lys20 is more frequent in squamous carcinoma than in adenocarcinoma 
(p=0.0002), is associated with advanced stage (p=0.018) and nodal 
metastasis (p=0.01) and correlates with a poor survival among stade 
I (p=0.026). Importantly, in adenocarcinoma, loss of trimethylation 
at Lys20 is associated with advanced stage (p=0.006) and correlates 
with a poor survival among stage I-II (p=0.0001) and N0 versus N1-2 
(p=0.013) tumors. Furthermore, the double loss of acetylation at Lys16 
and trimethylation at Lys20 is associated with a shorter survival in 
these patients as compared to the presence of either one or none of 
these alterations. 
Conclusion: These data provide the ﬁrst evidence of a global aberrant 
pattern of histone H4 modiﬁcation in lung tumors with hyperacety-
lation of Lysines 5 and 8 and loss of acetylation of lysine 16 and of 
trimethylation of Lysine 20. The frequent loss of lysine 20 trimethyl-
ation in squamous carcinoma, independently of the stage, suggests that 
it could be an early event in the carcinogenesis of this tumor type. In 
contrast, loss of lysine 20 trimethylation is less frequent in adenocar-
cinoma but correlates with a poor prognosis suggesting a role in the 
progression of these tumors.
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Identification of differentially methylated CpG Islands in the early 
stage of human pulmonary adenocarcinoma
Sun, Weihong; Iijima, Tatsuo; Kano, Junko; Anami, Yoichi; Inadome, 
Yukinori; Morishita, Yukio; Okubo, Chigusa; Noguchi, Masayuki 
Department of Pathology, Institute of Basic Medical Sciences, Gradu-
ate School of Comprehensive Human Sciences, University of Tsukuba, 
Tsukuba City, Japan
Background: In the development of cancer, a series of tumor suppres-
sor genes is inactivated by point mutation and chromosomal deletion. 
Aberrant methylation of CpG islands has recently been shown to serve 
as an alternative way of inactivating such genes in cancer. Methylation 
of cytosine residues in CpG dinucleotides is an extremely important 
epigenetic modiﬁcation of the eukaryotic genome that affects vari-
ous cell processes. Methylation is known to play an important role in 
neoplasia by inactivating tumor suppressor genes such as Rb, p16, and 
estrogen receptor. In this study we used CpG island ampliﬁcation and 
suppression subtractive hybridization to identify the aberrant methyla-
tion of CpG islands in A/J mouse lung adenoma, in order to clarify 
whether a hypermethylated homologue gene exists in human pulmo-
nary adenocarcinoma.
Methods: NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone)-
induced A/J mouse lung adenoma and normal tissue were used in this 
study. The histology of A/J mouse adenoma mimics the early stage of 
human pulmonary adenocarcinoma. The genomic DNA was extracted 
using standard procedures. The PCR-based methylated CpG island am-
pliﬁcation (MCA) technique was used for detection of methylated CpG 
islands. Suppression subtractive hybridization (SSH) and differential 
screening (DS) were used to identify the differentially methylated se-
quence in A/J mouse lung adenoma tissue. For the genes selected after 
SSH and DS analysis, quantitative Real-time PCR was used to check 
their expression level in A/J mouse lung adenoma tissue and normal tis-
sue. Using homoloGene software, human homologue genes were then 
detected. Real-time PCR was also performed to check the expression 
level of these genes in human lung adenocarcinoma and normal lung 
tissue. Bisulﬁte genomic sequencing was done to conﬁrm the methyla-
tion status of these genes in the promotor area.
